青岛普美圣医药科技

Promisun Pharmaceuticals is a clinical-stage biotechnology company headquartered in Qingdao, China, dedicated to developing innovative small molecule therapeutics for metabolic and inflammatory diseases. The company's primary focus is on the development of treatments for non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Its lead asset, PS-001, is a highly selective farnesoid X receptor (FXR) agonist that has demonstrated promising results in clinical trials. Additionally, Promisun is advancing a pipeline that includes thyroid hormone receptor beta (THR-beta) agonists and other candidates targeting oncology and chronic inflammation. The company aims to provide high-quality, affordable innovative medicines for patients worldwide through its robust internal R&D capabilities.